CSL Ltd. has opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site’s manufacturing plant for plasma products, is part of a $250 million expansion at its Broadmeadows site, which will play a larger role in the company’s global operations for late-stage development of new types of hemophilia products. It will produce novel recombinant therapies on a large scale for international clinical trials.   The first t...